Epoetin delta
Also known as: DeltaEPO, Dynepo, epoetin delta, PD-001, r-HuEPO delta
Source Epoetin delta at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human erythropoietin biosimilar used to treat anemia associated with chronic kidney disease, chemotherapy, and other conditions requiring increased red blood cell production.
Mechanism of Action
Binds and activates the erythropoietin receptor (EPOR) on erythroid progenitor cells, stimulating proliferation, differentiation, and survival of red blood cell precursors.
Routes of Administration
Goals & Uses
- Anemia in cancer chemotherapy patientsOncology/HematologyLow
- Anemia of chronic kidney diseaseHematologyHigh
- Reduction of allogeneic blood transfusionsPerioperative MedicineModerate
- Treatment of anemia in chronic renal failureHematology/NephrologyHigh
- Chemotherapy‑induced anemiaOncologyHigh
Contraindications
- Known hypersensitivity to epoetin productsImmunologicHigh
- Hypersensitivity to epoetin delta or excipientsImmunologicalHigh
- Uncontrolled hypertensionCardiovascularHigh
- Hemoglobin ≥12 g/dL in cancer patientsOncologyModerate
- Pure red cell aplasia (PRCA) due to prior ESA therapyImmunologicalHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- HypertensionCardiovascularCommonHigh blood pressure
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Thromboembolic eventsCardiovascularUncommon
- Pure red cell aplasia (PRCA)Immunological / HematologicalRare
- Thrombotic/thromboembolic eventsCardiovascular / HematologicalUncommon
Drug Interactions
- Antihypertensive agentsModerate
- CyclosporineModerate
- Iron supplementsLow
- Iron supplementationLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Cancer patients receiving curative-intent chemotherapyOncologyRelative
- Pediatric patientsAgeRelative
- Patients with cardiovascular diseaseComorbidityRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Anemia due to chronic kidney disease, Chemotherapy‑induced anemia, HIV‑related anemiaApproved as a biosimilar to epoetin alfa.
- United StatesInvestigationalNot FDA‑approved; under clinical investigation.
- United KingdomWithdrawnApproved: Anemia in chronic renal failureWas available as part of EU approval; no longer marketed following 2008 withdrawal.
Approved in the European Union as a biosimilar to epoetin alfa; not approved by the US FDA as of 2024.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Epoetin delta?
Recombinant human erythropoietin biosimilar used to treat anemia associated with chronic kidney disease, chemotherapy, and other conditions requiring increased red blood cell production.
What is Epoetin delta used for?
Epoetin delta is educationally associated with: Anemia in cancer chemotherapy patients, Anemia of chronic kidney disease, Reduction of allogeneic blood transfusions, Treatment of anemia in chronic renal failure, Chemotherapy‑induced anemia. Educational only — not medical advice.
How is Epoetin delta administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Epoetin delta?
Reported adverse effects include: Flu-like symptoms, Hypertension, Injection site reactions, Headache, Thromboembolic events, Pure red cell aplasia (PRCA), Thrombotic/thromboembolic events. This list is not exhaustive — consult a qualified clinician.
Who should avoid Epoetin delta?
Recorded contraindications: Known hypersensitivity to epoetin products, Hypersensitivity to epoetin delta or excipients, Uncontrolled hypertension, Hemoglobin ≥12 g/dL in cancer patients, Pure red cell aplasia (PRCA) due to prior ESA therapy. Consult a qualified clinician before use.